CNCE News and Press, Concert Pharmaceuticals Inc.

Summary Concert Pharmaceuticals, Inc. is a biotech buyout trading at a negative spread but with an interesting CVR attached. The CVR is based on two sales milestones. The 1st milestone appears quite achievable. The 2nd milestone can be considered a "free" option. Conce...

Concert Pharmaceuticals ( NASDAQ: CNCE ) announced Wednesday that the FDA allowed the company to keep its Breakthrough Therapy Designation for hair loss therapy deuruxolitinib, despite the agency’s approval of a rival therapy. In 2020, the FDA initially issued Breakthrough Ther...

Concert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation. Deuruxolitinib, an oral Janus kinase (JAK) inhibit...

NEW YORK, NY / ACCESSWIRE / January 24, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Concert Pharmaceuticals, Inc. (NASDAQ...

If all goes according to plan, Concert Pharmaceuticals (NASDAQ: CNCE) will soon cease to be an independent company. The biotech signed a deal to be acquired by a peer; as a result, its share price leaped more than 17% higher on the week, according to data compiled by S&P Global Mark...

Concert Pharmaceuticals ( NASDAQ: CNCE ) was up ~21% pre-market after Sun Pharma said it will acquire all the outstanding shares of the biotechnology company. Sun Pharma will pay an upfront cash payment of $8 per share, or equity consideration of $576M, and a contingent value rig...

Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma’s Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strength...

New Analyses Presented on the Effect of Baseline Severity and Duration of Current Episode of Hair Loss on Scalp Hair Regrowth Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the presentation of data from its THRIVE-AA1 Phase 3 clinical trial during the 12 ...

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT. A webcast of the presentation may be accessed in the Investors section of the Compa...

Concert Pharma ( NASDAQ: CNCE ) stock fell sharply on Monday despite the biopharma reporting a loss lighter than expected for third quarter. The Lexington-based drug developer focused on the treatment of autoimmune diseases reported a loss of $0.58 per share, notching ...